1. Craniopharyngiomas (CPs) are tumors that arise from the pituitary gland. They are of two types – Adamantinomatous (aCPs), and papillary (pCPs).
2. Genotyping tumors to identify therapeutic treatments is important
3. pCPs can respond to BRAF and MAPK-pathway inhibitors

1. Vemurafenib and combination of debrafenib and trametinib
2. Limitations: only 2 patients reported so far

    4· No adequate animal model for papillary craniopharyngioma exist

    5. Targeted NGS shows that CTNNB1 mutations are present in 74% of aCP cases

    6· 10% aCPs have mutations in BRAF oncogene (at low allelic frequency)

    7· CTNNB1 mutations can co-exist with BRAF indicating that they are not mutually exclusive and subtype specific